JPMorgan Chase & Co. Increases Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

JPMorgan Chase & Co. raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 191.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,744 shares of the biotechnology company’s stock after purchasing an additional 22,164 shares during the quarter. JPMorgan Chase & Co. owned about 0.11% of AnaptysBio worth $1,130,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Values First Advisors Inc. purchased a new stake in shares of AnaptysBio during the 3rd quarter valued at about $49,000. nVerses Capital LLC grew its position in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,400 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 2,600 shares in the last quarter. Point72 DIFC Ltd raised its stake in shares of AnaptysBio by 680.5% during the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 5,342 shares during the period. Finally, Intech Investment Management LLC acquired a new position in shares of AnaptysBio during the third quarter worth $229,000.

Insider Activity

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 65,184 shares of the business’s stock in a transaction on Monday, December 30th. The shares were purchased at an average price of $12.92 per share, with a total value of $842,177.28. Following the purchase, the director now directly owns 7,860,180 shares of the company’s stock, valued at approximately $101,553,525.60. The trade was a 0.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 33.70% of the company’s stock.

AnaptysBio Stock Up 1.3 %

ANAB opened at $16.85 on Friday. The company’s 50-day moving average price is $17.67 and its 200 day moving average price is $27.52. AnaptysBio, Inc. has a fifty-two week low of $12.51 and a fifty-two week high of $41.31. The firm has a market cap of $512.75 million, a price-to-earnings ratio of -2.77 and a beta of -0.02.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ANAB shares. JPMorgan Chase & Co. lowered their price target on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Wedbush reaffirmed an “outperform” rating and set a $40.00 target price (down from $42.00) on shares of AnaptysBio in a research report on Wednesday, December 11th. UBS Group increased their price target on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. HC Wainwright downgraded AnaptysBio from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $52.00 to $19.00 in a report on Wednesday, December 11th. Finally, Guggenheim reduced their target price on AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.45.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.